Skip to main content
Clinical Trials/ITMCTR2000002982
ITMCTR2000002982
Completed
Phase 2

A randomized, double-blinded, parallel-controlled, dose exploratory, multicentered-phase II clinical trial for the safety and effectiveness of hydroxysafflor yellow A (HSYA) injection in the treatment of&

Guangdong Hospital of traditional Chinese Medicine0 sitesTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Acute atherosclerotic thrombotic cerebral infarction
Sponsor
Guangdong Hospital of traditional Chinese Medicine
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Guangdong Hospital of traditional Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • (1\) Meet the diagnosis standard of stroke in traditional Chinese medicine and the diagnosis standard of blood stasis syndrome, western medicine diagnosed as atherosclerotic thrombotic cerebral infarction;
  • (2\) Apoplexy was divided into acute stage and middle meridian patients;
  • (3\) NIHSS score of neurological deficit 7 to 22;
  • (4\) The patients were anterior circulation infarction;
  • (5\) This is the first stroke, no previous history of stroke;
  • (6\) The course of disease should be within 7 days;
  • (7\) Aged 35\-75 years male and female;
  • (8\) After the onset of the disease, the patients had not been treated with intravenous thrombolysis, arterial thrombectomy or stenting;
  • (9\) Patients or legal guardians who have informed consent to accept the clinical trial and sign the informed consent.

Exclusion Criteria

  • (1\) Hemorrhagic cerebral infarction;
  • (2\) Patients with history of atrial fibrillation were considered as cardiogenic cerebral embolism;
  • (3\) The prothrombin time, prothrombin time and partial COA time 1\.5 ULN, or fibrinogen was less than 1\.5g/l, or there was active gastrointestinal bleeding and other bleeding tendency;
  • (4\) Patients with heart, liver, kidney, hematopoiesis and serious metabolic system diseases (alt, AST \>\=1\.5 ULN, or bun \>\=1\.2 ULN, Cr \> ULN), with cardiac function of grade 3 or above;
  • (5\) Pregnant or preparing pregnant and lactating women;
  • (6\) Patients with disabilities (blind, deaf, dumb, mental disorders and other causes of physical disability affecting the evaluation of neurological deficit) as prescribed by law;
  • (7\) Suspected history of alcohol or drug abuse, or other lesions that, in the judgment of the investigator, reduce or complicate enrollment;
  • (8\) Those with allergic constitution (refer to those who are allergic to more than two kinds of drugs or foods or known ingredients of this test drug) or those who are allergic to known ingredients of this drug;
  • (9\) Those who have used drugs known to damage the main organs within four weeks;
  • (10\) Patients who are participating in other clinical trials or who have participated in other drug clinical trials for less than 1 month;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
A randomized, double-blind, parallel-controlled, multicenter trial to evaluate the effectiveness and safety of Xiyanping injection combined with azithromycin and azithromycin in the treatment of mycoplasma pneumoniae pneumonia in childreMycoplasma pneumoniae pneumonia
ITMCTR2000003093The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Recruiting
Phase 4
A randomized, double-blind, parallel-controlled, multi-center clinical trial of Chinese medicine variety protection with Niuhuang Qinggan Capsule in the treatment of common cold (wind-heat syndrome)Common cold (wind-heat syndrome)
ITMCTR2200005537The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine
Recruiting
Phase 4
A randomized, double-blind, parallel-controlled, multi-center clinical trial of traditional Chinese medicine variety protection with Wuhu Oral Liquid in the treatment of acute soft tissue injury (Qi stagnation and blood stasis syndrome)acute soft tissue injury
ITMCTR2200005606onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Recruiting
Phase 4
A randomized, double-blind, parallel-controlled, multicentre clinical study to evaluate the efficacy and safety of Sechang Zhixie Powder in the treatment of acute watery diarrhea in childreAcute watery diarrhea
ITMCTR2100004284First Teaching Hospital of Tianjin University of TCM
Not yet recruiting
Phase 1
A randomized, double-blind, parallel-controlled, multi-center clinical trial of the effectiveness and safety of Fuyanxiao Capsule in the treatment of pelvic inflammatory diseases (damp-heat stasis syndrome)
ITMCTR2100005028Dongfang Hospital, Beijing University of Chinese Medicine